[
  {
    "question": "32 female with hx of parkinson disease came with parkinson symptoms, she is tailer with disabling symptoms including rest tremor, she had remarkable improvement with L-dopa (I believe they mean her cousin or so) what to do",
    "option_a": "(Dopamine agonist) is less ideal because dopamine agonists, while useful in younger patients to delay levodopa complications, do not control disabling symptoms as effectively as levodopa. Option B (Levodopa) is correct given its superior efficacy in relieving motor symptoms in this patient with a previous history of remarkable improvement.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is characterized by dopamine deficiency in the basal ganglia, and levodopa remains the gold standard treatment for alleviating motor symptoms by replenishing dopamine levels. The hallmark of PD is the degeneration of dopaminergic neurons in the substantia nigra. Levodopa works by crossing the blood\u2013brain barrier and being converted to dopamine, which then replenishes the depleted levels leading to improvement in motor function, particularly addressing bradykinesia and tremor. In a young patient with disabling motor symptoms and a documented excellent response to levodopa, the direct dopamine precursor therapy is preferred over dopamine agonists, which, although useful in delaying motor complications in younger PD patients, do not offer the same degree of symptomatic relief, especially for disabling tremor. When evaluating a young patient with PD, differentials include conditions such as drug-induced parkinsonism or atypical parkinsonian syndromes. A positive and robust response to levodopa reinforces the diagnosis of idiopathic PD. First-line treatment for disabling motor symptoms in PD is levodopa. Although dopamine agonists may be considered to postpone motor complications in early disease, they are less effective than levodopa in controlling tremor and bradykinesia. In pregnant or lactating patients, levodopa is often continued if the benefits to the mother outweigh the potential risks, with multidisciplinary management and careful monitoring. Option A (Dopamine agonist) is less ideal because dopamine agonists, while useful in younger patients to delay levodopa complications, do not control disabling symptoms as effectively as levodopa. Option B (Levodopa) is correct given its superior efficacy in relieving motor symptoms in this patient with a previous history of remarkable improvement. 1. Levodopa is the most effective agent for controlling motor symptoms in PD. 2. Dopamine agonists are generally considered when trying to delay long-term levodopa complications, but not when symptoms are disabling. 3. Documented levodopa responsiveness confirms the diagnosis of PD. Updated guidelines continue to recommend levodopa as the cornerstone treatment for moderate to severe PD. Research is also exploring individualized therapy with consideration of patient age, cognitive status, and motor disability.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Female with hx of action and intention tremor, dropping things, slightly asymmetric family hx what is the dx",
    "option_a": "(Physiological tremor) is incorrect because it is normally low amplitude and does not cause significant functional impairment like dropping objects. Option B (Essential tremor) is correct as it best fits the clinical picture of an action tremor with a positive family history and functional impact. Option D is not applicable based on the typical presentation of ET. Other options (if provided) would likely represent alternative tremor etiologies which do not match the clinical scenario.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential tremor (ET) is one of the most common movement disorders characterized by an action tremor that can be familial. It is distinct from physiological tremor, which is a normal phenomenon. The underlying mechanism of ET is not fully understood, but it is thought to involve abnormal oscillatory activity within the cerebello-thalamo-cortical circuits. Genetic factors play a role, as evidenced by the familial aggregation, though variable penetrance can lead to asymmetry in the family history. ET typically presents with a postural and action tremor that worsens with movement, often interfering with activities of daily living such as holding objects. The presence of an intention component can be seen, although it is classically described as an action tremor. A positive family history further supports the diagnosis. Differentiating ET from other tremor types is critical. Differential diagnoses include Parkinsonian tremor (typically resting, with rigidity and bradykinesia), cerebellar tremor (usually more pronounced with intention and accompanied by other cerebellar signs), and drug-induced tremor. A focused history and clinical examination help in the differentiation. First-line treatments for ET include non-selective beta-blockers (e.g., propranolol) and primidone. In patients who are pregnant or lactating, risks and benefits must be weighed carefully; for example, beta-blockers carry potential fetal risks and should be used under close monitoring, while primidone is generally avoided in pregnancy due to limited safety data. Second-line agents include topiramate and benzodiazepines. Option A (Physiological tremor) is incorrect because it is normally low amplitude and does not cause significant functional impairment like dropping objects. Option B (Essential tremor) is correct as it best fits the clinical picture of an action tremor with a positive family history and functional impact. Option D is not applicable based on the typical presentation of ET. Other options (if provided) would likely represent alternative tremor etiologies which do not match the clinical scenario. 1. Essential tremor is an action tremor that can be familial and may be asymmetric. 2. It is a diagnosis of exclusion after ruling out other tremor disorders such as Parkinson\u2019s disease or cerebellar tremor. 3. Beta-blockers and primidone remain the cornerstone of ET management. Recent guidelines and consensus statements highlight the importance of clinical diagnosis in ET, with ongoing research examining the genetic underpinnings and potential new therapeutic targets. Updated meta-analyses continue to support the use of beta-blockers as first-line therapy, while also calling for careful medication selection in special populations such as pregnant women.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "PD for 7 yrs, Severe disabling dyskinesia on medical therapy, has mild cognitive impairment",
    "option_a": "(DBS to GPi) is correct. It is preferred for patients with severe dyskinesias and cognitive concerns. Option B (DBS to STN) is incorrect because STN stimulation is more likely to produce cognitive side effects and is less ideal in the setting of pre",
    "option_b": "",
    "option_c": "(DBS to VIM) is not appropriate as it targets tremor control and does not address dyskinesias. Option D (other nuclei) is not supported by current evidence for managing dyskinesias in PD.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Deep Brain Stimulation (DBS) is a well-established treatment for advanced Parkinson\u2019s disease (PD) that is refractory to medical therapy. There are several targets for DBS, including the subthalamic nucleus (STN), globus pallidus interna (GPi), and ventral intermediate nucleus (VIM) of the thalamus. In PD, dopaminergic neuron degeneration leads to motor fluctuations and dyskinesias. DBS modulates abnormal neuronal activity in the basal ganglia-thalamo-cortical circuits. GPi stimulation is particularly effective for suppressing dyskinesias because it directly modulates the output of the basal ganglia, and it is known to have a more favorable cognitive profile than STN stimulation. A patient with advanced PD who has severe, disabling dyskinesias and mild cognitive impairment is best managed with a DBS target that both improves motor symptoms and minimizes further cognitive risk. GPi DBS is preferred in this clinical context because it is less likely to worsen cognitive function, unlike STN DBS, which, although effective for bradykinesia and motor fluctuations, may exacerbate cognitive deficits. Before proceeding with DBS, patients undergo a thorough evaluation including neuroimaging, neuropsychological assessment, and evaluation of motor symptom severity and dyskinesias. Differential considerations for DBS target include patients whose primary issue is tremor (VIM DBS) or those with predominant bradykinesia/motor fluctuations (STN DBS). The patient\u2019s cognitive status is a critical factor in the decision-making process. First-line surgical management for disabling dyskinesias in a PD patient with mild cognitive impairment is GPi DBS. This approach minimizes the risk of further cognitive decline while effectively reducing dyskinesias. In pregnant or lactating patients, surgical interventions like DBS are rarely performed due to the surgical and anesthesia-related risks; however, when indispensable, a multidisciplinary team would plan timing and management carefully. Option A (DBS to GPi) is correct. It is preferred for patients with severe dyskinesias and cognitive concerns. Option B (DBS to STN) is incorrect because STN stimulation is more likely to produce cognitive side effects and is less ideal in the setting of pre-existing cognitive impairment. Option C (DBS to VIM) is not appropriate as it targets tremor control and does not address dyskinesias. Option D (other nuclei) is not supported by current evidence for managing dyskinesias in PD. 1. GPi DBS is the preferred target in PD patients with disabling dyskinesias and cognitive impairment. 2. STN DBS, while effective for bradykinesia, carries a higher risk for cognitive side effects. 3. Comprehensive pre-surgical evaluation is essential to tailor DBS target selection. Recent studies and consensus guidelines emphasize the importance of individualized DBS target selection based on the symptom profile and neuropsychological status. Current research supports GPi DBS as having a safer cognitive profile, which is increasingly recognized in clinical practice when managing patients with PD who have mild cognitive impairment.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario suggestive of wilson, parkinson, dystonia tx",
    "option_a": "(Penicillamine) is correct because it directly addresses the copper overload, particularly effective for neurological manifestations when initiated early. Other options (like zinc and trientine) are important but were not provided in the answer set, making penicillamine the best choice in this scenario.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "Wilson disease is an autosomal recessive disorder of copper metabolism resulting in toxic copper accumulation in organs, particularly the liver and brain. Neurological manifestations such as parkinsonism and dystonia occur due to copper deposition in the basal ganglia. Mutations in the ATP7B gene impair hepatic copper excretion. Accumulated copper subsequently deposits in various tissues, most notably the liver and central nervous system. In the brain, copper-induced oxidative stress and neuronal injury underlie the development of movement disorders including dystonia and parkinsonism. Patients may present with hepatic dysfunction (cirrhosis, abnormal liver enzymes) or neuropsychiatric symptoms, such as abnormal movements (tremor, dystonia, parkinsonian features) and cognitive changes. Ocular findings, like Kayser-Fleischer rings, also serve as a clinical clue. Key diagnostics include serum ceruloplasmin (usually low), increased urinary copper excretion, and slit-lamp examination for Kayser-Fleischer rings. Liver biopsy and genetic testing can further support the diagnosis. Differential diagnoses include other causes of movement disorders and hepatic encephalopathies. First-line treatment involves chelation of copper. Penicillamine is the standard initial therapy to promote urinary copper excretion. Alternatives include trientine (a less immunogenic chelator) and zinc, which decreases copper absorption by inducing metallothionein in enterocytes. In pregnant or lactating women, risk\u2010benefit discussion is essential; penicillamine has been used cautiously in pregnancy at lower doses, while zinc might be considered due to its safety profile. Lifelong therapy and monitoring are required. Option A (Penicillamine) is correct because it directly addresses the copper overload, particularly effective for neurological manifestations when initiated early. Other options (like zinc and trientine) are important but were not provided in the answer set, making penicillamine the best choice in this scenario. 1. Always look for Kayser-Fleischer rings in suspected cases. 2. Early initiation of chelation therapy prevents irreversible neurological damage. 3. Monitoring copper levels and clinical symptoms is essential throughout treatment. Recent guidelines emphasize early diagnosis and initiation of chelation therapy in Wilson disease. Updated recommendations reflect that while penicillamine remains the first-line therapy, alternatives like trientine are increasingly considered in patients who are intolerant or experience adverse reactions.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "20 yo with ataxia, spasticity, sensorimotor neuropathy hypometric saccade, brain MRI showed mild cerebellar atrophy, normal immunoglobulin high alfa fetoprotein, echo normal what is the dx",
    "option_a": "(Friedreich ataxia) is excluded due to its different systemic associations (such as cardiomyopathy and diabetes) and typically normal AFP. Options C (OPA1 related pathology) and D (OPA2) are primarily associated with optic atrophy rather than the broad neurological picture seen here. Option B (Ataxia telangiectasia) best explains the elevated AFP, cerebellar changes, and constellation of symptoms even if telangiectasias are not yet apparent.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Ataxia telangiectasia (AT) is a rare neurodegenerative disorder characterized by progressive ataxia, oculomotor abnormalities, and immunodeficiency. Despite classically presenting with telangiectasias, early disease may lack these ocular findings. AT is caused by mutations in the ATM gene, which plays a crucial role in the repair of double-stranded DNA breaks. The resultant genomic instability leads to neurodegeneration, immunological abnormalities, and elevated alpha-fetoprotein (AFP) levels. Although immunoglobulin levels are often low, some patients may have near-normal values early on. The clinical picture with ataxia, spasticity, sensorimotor neuropathy, and oculomotor findings (such as hypometric saccades) fits with AT. Elevated AFP is a hallmark, and cerebellar atrophy on MRI further supports the diagnosis. Telangiectasias might develop later in the disease course. Work-up includes measurement of serum AFP, immunoglobulin levels, and genetic testing for ATM mutations. Differential diagnoses include Friedreich ataxia, which usually shows cardiomyopathy and does not have elevated AFP, and other hereditary ataxias that lack the combination of oculomotor abnormalities and AFP elevation. Management is primarily supportive as no cure exists. Treatment includes physical therapy, occupational therapy, and immunoglobulin replacement in cases with significant immunodeficiency. Close monitoring for malignancies is advised. In pregnancy and lactation, management remains supportive; multidisciplinary coordination is necessary with maternal-fetal medicine, particularly if immunosuppressive therapies become necessary. Option A (Friedreich ataxia) is excluded due to its different systemic associations (such as cardiomyopathy and diabetes) and typically normal AFP. Options C (OPA1 related pathology) and D (OPA2) are primarily associated with optic atrophy rather than the broad neurological picture seen here. Option B (Ataxia telangiectasia) best explains the elevated AFP, cerebellar changes, and constellation of symptoms even if telangiectasias are not yet apparent. 1. Elevated AFP in a young patient with ataxia is highly suggestive of AT. 2. The absence of telangiectasias does not rule out AT in its early stages. 3. Genetic counseling is important given the autosomal recessive inheritance pattern. Recent studies have given insights into the variability of immunodeficiency seen in AT, with some patients having near-normal immunoglobulin levels initially. Advances in genetic testing further help to confirm the diagnosis and allow for early supportive intervention.",
    "exam_year": "2022",
    "exam_type": "Part II",
    "image_url": "page_29.png"
  },
  {
    "question": "Clear scenario of vascular PD what to do",
    "option_a": "(Control hypertension and vascular risk factors) is correct because it directly addresses the underlying cause of vascular parkinsonism. Options suggesting a primary use of levodopa (or ignoring vascular management) are less effective due to the ischemic etiology of the disorder. The marked answer (Option C) is incorrect as it does not emphasize the essential vascular risk factor control.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Vascular parkinsonism is a form of secondary parkinsonism resulting from cerebrovascular disease. Its pathogenesis is linked to vascular insults that predominantly affect lower-body motor function. Ischemic damage in subcortical structures, particularly in the basal ganglia and white matter, leads to the interruption of motor pathways. This vascular injury manifests with parkinsonian features, especially affecting lower extremity function and gait. Patients often present with lower body parkinsonism characterized by gait impairment and rigidity predominantly in the legs. Tremor is less common, and the response to standard dopaminergic therapy (e.g., levodopa) is typically poor. The clinical course is closely linked to the control of vascular risk factors such as hypertension. Brain imaging (MRI) can reveal evidence of chronic ischemic changes in the basal ganglia and subcortical regions. Differential diagnoses include idiopathic Parkinson\u2019s disease (which typically features a good response to levodopa and a presence of rest tremor) and atypical parkinsonian syndromes like progressive supranuclear palsy (PSP). Detailed history and neuroimaging help in distinguishing these conditions. The cornerstone of management is aggressive control of vascular risk factors, particularly hypertension. First-line management includes optimizing blood pressure, lipid levels, and glycemic control to prevent further cerebrovascular injury. Dopaminergic therapy with levodopa is generally less effective, so the focus remains on controlling the underlying vascular pathology. In pregnant or lactating patients, antihypertensive agents with good safety profiles such as labetalol or methyldopa are preferred, while management of parkinsonian features should be cautiously approached with a multidisciplinary team. Option A (Control hypertension and vascular risk factors) is correct because it directly addresses the underlying cause of vascular parkinsonism. Options suggesting a primary use of levodopa (or ignoring vascular management) are less effective due to the ischemic etiology of the disorder. The marked answer (Option C) is incorrect as it does not emphasize the essential vascular risk factor control. 1. Vascular parkinsonism often presents with a lower-body predominance and minimal tremor. 2. Levodopa response is generally unsatisfactory in vascular parkinsonism. 3. Comprehensive cardiovascular risk management is key to preventing progression. Recent guidelines and studies have reinforced the importance of managing vascular risk factors in patients with parkinsonian symptoms secondary to cerebrovascular disease. There is an increasing emphasis on non-dopaminergic strategies in these patients.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario patient had parkinsonism restricted to LL with slowing, no tremor responding to L-dopa what is the dx",
    "option_a": "(Vascular Parkinsonism) is correct as it best fits the clinical picture: lower limb restricted parkinsonism without tremor and with some levodopa responsiveness. Option B (PSP) is unlikely due to the absence of vertical gaze palsy and early postural instability, while Option C (a fictitious syndrome) does not exist in the literature.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Vascular parkinsonism is recognized as a subtype of secondary parkinsonism, typically associated with ischemic damage to subcortical areas that affect lower motor functions. It often presents with symptoms predominantly affecting the lower limbs. Chronic cerebrovascular disease leads to small vessel ischemic changes, particularly in the basal ganglia or subcortical white matter regions. This results in disruption of motor control, which usually manifests as slowness of movements and gait difficulties. The described clinical scenario \u2013 parkinsonism restricted to the lower limbs, absence of tremor, and a positive (even if variable) response to levodopa \u2013 is more suggestive of vascular parkinsonism rather than idiopathic Parkinson\u2019s disease or atypical parkinsonian syndromes like PSP. Although dopaminergic response in vascular parkinsonism is often limited, some patients may still demonstrate improvement with levodopa. Diagnosis is based on clinical features corroborated by neuroimaging findings showing vascular changes, especially in the subcortical regions. Differential diagnoses include idiopathic Parkinson\u2019s disease (typically with prominent tremor and a better levodopa response) and progressive supranuclear palsy (characterized by early gait instability and gaze palsy). Detailed patient history and imaging studies help in differentiating these conditions. Management focuses on controlling vascular risk factors such as hypertension, diabetes, and hyperlipidemia. Although levodopa trials can be considered, their benefits are usually modest. In pregnant or lactating patients, management of vascular risk factors should involve agents with established safety profiles, and any parkinsonian treatments should be employed with caution and in consultation with neurology and obstetrics specialists. Option A (Vascular Parkinsonism) is correct as it best fits the clinical picture: lower limb restricted parkinsonism without tremor and with some levodopa responsiveness. Option B (PSP) is unlikely due to the absence of vertical gaze palsy and early postural instability, while Option C (a fictitious syndrome) does not exist in the literature. 1. Vascular parkinsonism should be suspected in patients with lower extremity predominant parkinsonian symptoms. 2. Neuroimaging is crucial to identify the extent of vascular changes. 3. Control of vascular risk factors is the mainstay of treatment. Recent research underscores the heterogeneity in response to levodopa among patients with vascular parkinsonism. Current guidelines recommend prioritizing vascular risk reduction and caution against excessive reliance on dopaminergic therapies in these cases.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Pt presented with dystopia, tremor and Parkinsonism, MRI showed bilateral BG and brainstem hyper intensity. What you will give?",
    "option_a": "levodopa",
    "option_b": "D-penicillamine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "This scenario is typical of Wilson\u2019s disease, an autosomal recessive disorder of copper metabolism. Patients often present with neuropsychiatric manifestations including movement disorders such as dystonia, tremor, and parkinsonism, accompanied by characteristic neuroimaging findings. Wilson\u2019s disease results from mutations in the ATP7B gene, impairing hepatic copper excretion and leading to copper accumulation in various tissues, particularly the liver, brain (notably the basal ganglia and brainstem), and cornea. The copper deposition induces oxidative stress and neuronal injury, giving rise to the diverse neurological symptoms seen in the disease. The patient\u2019s presentation with dystonic posturing, tremor, and parkinsonian features, together with MRI findings of bilateral basal ganglia and brainstem hyperintensities, strongly supports the diagnosis of Wilson\u2019s disease. Other clinical hallmarks may include hepatic dysfunction and the presence of Kayser-Fleischer rings on slit-lamp examination. Beyond neuroimaging, the diagnostic workup includes serum ceruloplasmin levels (often low), 24-hour urinary copper excretion (elevated), liver function tests, and ophthalmologic examination for Kayser-Fleischer rings. Differential diagnoses include other movement disorders such as Parkinson\u2019s disease or atypical parkinsonian syndromes; however, the combination of hepatic involvement, younger age, and characteristic imaging favors Wilson\u2019s disease. The first-line treatment for Wilson\u2019s disease is chelation therapy, with D-penicillamine being a widely used agent. Alternatives include trientine and zinc therapy, particularly for maintenance. In pregnancy and lactation, treatment requires a careful balance between maternal benefits and fetal risks; zinc may be preferred in some cases due to a better safety profile, though chelators can be continued if benefits outweigh potential risks. Regular monitoring for side effects is critical. Option A (levodopa) is primarily used in idiopathic Parkinson\u2019s disease and would not address the underlying copper toxicity. Option B (D-penicillamine) is correct as it chelates copper, reducing its deposition in tissues. Options C and D are not provided or relevant, making B the best choice. \u2022 Always consider Wilson\u2019s disease in younger patients with movement disorders and hepatic signs. \u2022 Look for Kayser-Fleischer rings as a useful clinical clue. \u2022 Early initiation of chelation therapy can prevent irreversible organ damage. Recent guidelines continue to endorse D-penicillamine as a first-line chelator for Wilson\u2019s disease, while emphasizing the need for regular monitoring of adverse effects and dose adjustment. Emerging research is investigating alternative agents and the long-term benefits of zinc in maintenance therapy, especially in women of childbearing age.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Case of essential palatal myoclonus ask about investigations",
    "option_a": "Temoromandibular joint CT",
    "option_b": "MRI audio canal",
    "option_c": "EEG",
    "option_d": "plain MRI",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential palatal myoclonus is a rare movement disorder characterized by rhythmic, involuntary contractions of the palate. It is typically idiopathic, meaning no underlying structural lesion is identified, as opposed to symptomatic palatal tremor which is secondary to identifiable brainstem pathology. In essential palatal myoclonus, the pathophysiology is not fully understood; however, it is believed to involve abnormal rhythmic activity in the brainstem or in the neural circuits controlling the muscles of the soft palate. In symptomatic cases, lesions in the Guillain\u2013Mollaret triangle (red nucleus, inferior olivary nucleus, and dentate nucleus) are implicated. Clinically, patients often report a clicking sound (due to eustachian tube dysfunction) and visible rhythmic movements of the soft palate. The absence of other neurological deficits helps support the diagnosis of the essential form. The investigation of choice is a plain MRI of the brain, which helps exclude structural abnormalities in the brainstem or cerebellum that would indicate a symptomatic cause. Differential diagnoses include symptomatic palatal tremor (which would reveal lesions in the Guillain\u2013Mollaret triangle) and epileptic myoclonus (where an EEG would be more informative). Although the question focuses on investigations, treatment options for essential palatal myoclonus include medications such as clonazepam or botulinum toxin injections for symptomatic relief. In pregnancy and lactation, benzodiazepines should be used with caution due to potential risks, and non-pharmacologic interventions may be considered. Option A (Temporomandibular joint CT) is not relevant to palatal myoclonus. Option B (MRI of the audio canal) does not address the central neurological origin of the condition. Option C (EEG) is indicated if seizures are suspected, which is not the case here. Option D (plain MRI) is the most appropriate investigation to evaluate for structural brain lesions and confirm the essential (idiopathic) nature of the myoclonus. \u2022 Essential palatal myoclonus often presents with clicking sounds due to rhythmic palatal contractions. \u2022 A normal plain MRI supports the diagnosis by excluding secondary causes. \u2022 Distinguishing between essential and symptomatic forms is key to targeted management. Recent literature underscores the role of MRI in differentiating essential from symptomatic palatal tremor. While there is ongoing research into refined imaging techniques and treatment modalities, plain MRI remains the first-line investigation due to its availability and effectiveness in excluding underlying lesions.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Levedopa improve which symptom in PsP?",
    "option_a": "Bradykinasia",
    "option_b": "Tremor",
    "option_c": "Gaza",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is a neurodegenerative tauopathy that presents with parkinsonian features. Although patients with PSP generally show a poor overall response to dopaminergic therapy, some aspects, particularly bradykinesia, may exhibit modest improvement with levodopa. PSP is characterized by the abnormal accumulation of tau protein in neural tissues, especially in the brainstem (including the midbrain) and basal ganglia. This leads to widespread neuronal degeneration, impacting motor control, balance, and ocular movements. The dopaminergic deficit in PSP differs from that in idiopathic Parkinson\u2019s disease, which explains the limited response to levodopa. Clinically, PSP typically manifests with early postural instability, gait disturbances, and rigid axial features. Although levodopa is the mainstay treatment for Parkinson\u2019s disease, in PSP it may only transiently or partially improve bradykinesia (slowness of movement) without significantly affecting other symptoms such as gait or oculomotor deficits. The diagnosis of PSP is primarily clinical, based on criteria including early falls, vertical gaze palsy, and axial rigidity. Neuroimaging\u2014especially MRI showing midbrain atrophy (often described as the 'hummingbird sign')\u2014supports the diagnosis. Differential diagnoses include idiopathic Parkinson\u2019s disease (which shows a better levodopa response), multiple system atrophy, and corticobasal degeneration. Management is largely supportive. A trial of levodopa is recommended even if the response is modest, primarily for bradykinetic features. Other treatment options include physical therapy, fall prevention strategies, and symptomatic management of other neurological deficits. In pregnancy and lactation, dopaminergic medications require close monitoring; although levodopa is used cautiously, the benefits may outweigh the risks in carefully selected cases. Option A (Bradykinasia) is correct because, if any improvement is seen with levodopa in PSP, it is most often in the bradykinetic aspects. Option B (Tremor) is not typically a prominent or responsive feature in PSP. Option C (Gaza, likely intended to mean gait) is usually unresponsive to levodopa in PSP due to predominant axial and postural impairments. \u2022 PSP is often identified by early falls, axial rigidity, and the 'hummingbird sign' on MRI. \u2022 Although levodopa response in PSP is generally poor, a modest improvement in bradykinesia may be observed. \u2022 Differentiation from Parkinson\u2019s disease is crucial as PSP has a distinct clinical course and management strategy. Current research confirms that while levodopa is a cornerstone therapy in Parkinson\u2019s disease, its benefit in PSP is limited. Recent guidelines emphasize symptomatic and supportive care in PSP, with ongoing studies investigating novel tau-targeted therapies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about woman 3 years suffered from fallness and unsteady gait, with urinary urgency and then incontinence. MRI showed atrophy of midbrain. What is diagnosis?",
    "option_a": "msa",
    "option_b": "psp",
    "option_c": "nph",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "This case scenario describes a woman with a multi-year history of falls, unsteady gait, and urinary dysfunction, combined with MRI findings of midbrain atrophy. These features are most consistent with Progressive Supranuclear Palsy (PSP). PSP involves the accumulation of tau protein, leading to neurodegeneration primarily affecting the midbrain, basal ganglia, and brainstem. The resulting atrophy, especially in the midbrain, is a hallmark of PSP and underlies the characteristic motor and autonomic symptoms observed. Patients with PSP commonly present with early falls, gait instability, axial rigidity, and urinary urgency progressing to incontinence. The MRI finding of midbrain atrophy (often illustrated by the 'hummingbird sign') supports the diagnosis of PSP as opposed to other neurodegenerative conditions. The differential diagnosis includes Multiple System Atrophy (MSA) and Normal Pressure Hydrocephalus (NPH). MSA typically demonstrates additional features such as severe autonomic dysfunction and cerebellar signs with a 'hot cross bun' sign on MRI, while NPH is characterized by ventriculomegaly with a clinical triad of gait disturbance, dementia, and urinary incontinence. The presence of midbrain atrophy specifically points to PSP. Management of PSP is primarily supportive. A trial of levodopa is generally recommended, though the benefit is often modest. Treatment focuses on physical therapy, fall prevention, and symptomatic management of urinary dysfunction. In pregnant or lactating women, the use of dopaminergic agents is cautious; non-pharmacologic interventions are emphasized and any medication use requires careful risk-benefit analysis in accordance with current guidelines. Option A (MSA) is less likely because MSA is typically associated with different MRI findings (e.g., hot cross bun sign) and more prominent autonomic dysfunction. Option B (PSP) is the correct diagnosis given the clinical and radiographic features. Option C (NPH) would be suggested by ventriculomegaly rather than midbrain atrophy. \u2022 The \u2018hummingbird sign\u2019 on MRI is highly suggestive of PSP. \u2022 Early falls and axial rigidity are characteristic findings of PSP. \u2022 Distinguishing PSP from similar conditions like MSA and NPH is critical for proper management. Latest clinical guidelines reaffirm that PSP has a poor response to dopaminergic therapy and mainly advocate supportive care. Ongoing research is exploring novel therapies targeting tau pathology, but no disease-modifying treatments are available at present.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Case of 50 year old female presenting c/o imbalance, tremor. MRI showed bilateral hypertense Cerbellear pedncle",
    "option_a": "Fragile X",
    "option_b": "paraneplastic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder seen in carriers of the FMR1 gene premutation. It typically presents with intention tremor, balance issues, and cerebellar signs. Radiologically, the MCP (middle cerebellar peduncle) sign \u2013 bilateral hyperintensities on T2-weighted MRI \u2013 is characteristic. FXTAS is thought to be due to RNA toxicity from a premutation expansion (55\u2013200 CGG repeats) in the FMR1 gene. This leads to the formation of intranuclear inclusions in neurons and astrocytes, resulting in white matter changes particularly affecting the cerebellum and its connections, as seen in the bilateral hyperintense cerebellar peduncles on MRI. Patients typically present in their 50s or later with hand tremor, gait ataxia, and, less frequently, cognitive deficits or parkinsonism. Although FXTAS is more common in males, females can be affected though often with a milder presentation due to X\u2010inactivation. Diagnosis is based on clinical features supported by neuroimaging (showing the MCP sign) and confirmed with genetic testing for the FMR1 premutation. Differential diagnoses include paraneoplastic cerebellar degeneration, multiple system atrophy (cerebellar type), and other causes of cerebellar ataxia. Management is supportive and symptomatic. First-line treatments include beta-blockers or primidone for tremor and physical therapy for ataxia. Advanced cases may also benefit from occupational, speech, and cognitive therapies. In pregnancy or lactation, any medication should be carefully evaluated for safety with obstetric consultation, and nonpharmacological therapies should be prioritized. Option A (Fragile X) is correct when interpreted in the context of FXTAS, which is associated with a premutation in the FMR1 gene. Option B (paraneoplastic) is less likely given the typical age, genetic association, and MRI findings seen in FXTAS. 1) The 'MCP sign' on MRI is almost pathognomonic for FXTAS. 2) FXTAS should be considered in older patients with tremor and ataxia, even in females, albeit with milder manifestations. 3) Confirmatory diagnosis relies on genetic testing for FMR1 premutations. Recent guidelines emphasize the importance of early recognition of FXTAS and confirmation with genetic testing. Ongoing research is focused on understanding the RNA toxicity mechanisms and identifying potential neuroprotective therapies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Rostral Vermis defect",
    "option_a": "Wide base gait",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "The cerebellar vermis, especially its rostral (anterior) portion, plays a critical role in maintaining axial stability and coordinating gait. Lesions here lead to truncal ataxia and a compensatory wide-based gait. Damage to the rostral cerebellar vermis disrupts the integration of proprioceptive and vestibular signals required for maintaining balance. This dysfunction results in instability of the trunk, prompting a wide-based gait for compensation. Patients with a rostral vermis lesion often exhibit a wide-based gait with difficulty in balancing while walking, even though limb coordination (seen in cerebellar hemisphere lesions) might be relatively preserved. The diagnosis is primarily clinical, supported by neuroimaging (MRI) which can localize cerebellar lesions. Differential diagnoses include sensory ataxia (where proprioceptive loss is evident) and cerebellar hemisphere lesions that cause limb dysmetria rather than a truncal imbalance. Management includes physical therapy focusing on balance and gait training. In cases where an underlying pathology is identified (like a vascular or demyelinating cause), specific treatment is initiated. During pregnancy or lactation, non-pharmacological interventions such as supervised physiotherapy are particularly favored given medication safety concerns. Option A (Wide base gait) is correct because disruption of the rostral vermis directly correlates with a wide-based gait. The other options, though not listed, would likely not align with the specific symptomatology of a rostral vermis defect. 1) Lesions in the midline (vermis) result in truncal ataxia rather than limb ataxia. 2) A wide-based gait is a compensatory response to instability. 3) Differentiating between cerebellar and sensory causes of ataxia is critical in guiding management. Current clinical guidelines support early intervention with rehabilitative therapies in cerebellar ataxia, emphasizing tailored physiotherapy programs to improve stability and reduce fall risk.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Focal dystonia ?? Torticollis which improve when touching the face!",
    "option_a": "shows good response to sentry trick",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Focal dystonia, such as cervical dystonia (torticollis), often exhibits a phenomenon known as a 'sensory trick' or 'geste antagoniste'\u2014where a specific maneuver, like touching the face, temporarily improves the dystonic posture. The sensory trick is thought to modulate abnormal proprioceptive feedback loops and transiently normalize the sensorimotor integration in the basal ganglia and cerebellar circuits, leading to temporary relief of dystonic contractions. In patients with cervical dystonia, the ability to alleviate symptoms by lightly touching the face or chin is a key clinical feature and can help differentiate dystonia from other movement disorders. Diagnosis is based on clinical evaluation, observing both the dystonic posturing and the improvement with a sensory trick. Differential diagnoses include conditions like Parkinson\u2019s disease and tardive dyskinesia, which do not exhibit relief with a sensory maneuver. First-line treatment for cervical dystonia typically includes botulinum toxin injections, which target overactive muscles. Oral medications (anticholinergics or muscle relaxants) and physical therapy might be used as adjuncts. In pregnancy and lactation, the use of botulinum toxin is relatively safe when administered by experienced clinicians after carefully weighing the risks and benefits, and non-pharmacological measures like physical therapy are encouraged. Option A is correct as it specifically describes the phenomenon of a 'sensory trick' which is classically seen in focal dystonias such as torticollis. The other options, while not provided, would not typically account for this distinct clinical maneuver. 1) The sensory trick is almost pathognomonic for cervical dystonia. 2) Botulinum toxin injected into overactive muscles remains the mainstay of symptomatic management. 3) Sensory tricks can help differentiate dystonia from other involuntary movements. Recent research continues to support botulinum toxin as the best evidence-based treatment for focal dystonias, with ongoing studies aimed at refining injection techniques and exploring adjunct therapies. Non-pharmacological strategies are also under evaluation for long-term management.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with startle hey sudden closure of his eyelids, worse with cold etc. what is the gene or somthing else",
    "option_a": "chloride channel",
    "option_b": "K channel",
    "option_c": "Na Channel",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "Paramyotonia congenita is a skeletal muscle channelopathy that presents with myotonia (difficulty relaxing muscles) which is paradoxically worsened by exposure to cold. It frequently affects muscles around the face, leading to phenomena like eyelid closure myotonia. The disorder is due to a mutation in the SCN4A gene, which affects the voltage-gated sodium channels in muscle cell membranes. This mutation impairs muscle fiber repolarization and leads to prolonged depolarization, which manifests as myotonia. Patients typically present with stiffness, particularly after exposure to cold, and may have difficulty with tasks involving facial muscles such as keeping the eyes open. The worsening of symptoms with cold exposure differentiates it from chloride channelopathies, where a 'warm-up' phenomenon is often noted. Diagnosis is confirmed through clinical evaluation, electromyography (EMG), and genetic testing for mutations in the SCN4A gene. Differential diagnoses include myotonia congenita due to chloride channel mutations (CLCN1), which typically shows improvement with repeated activity rather than worsening with cold, as well as myotonic dystrophies which have a broader systemic involvement. Management primarily involves avoiding cold and other triggers. Pharmacological treatment includes sodium channel blockers such as mexiletine, which can help to reduce myotonia. In pregnancy and lactation, the selection of medications requires careful consideration, and non-pharmacological interventions (like avoiding cold exposure) are prioritized. Consultation with neuromuscular specialists and obstetric teams is recommended for individualized management. Option A (chloride channel) is incorrect because chloride channel mutations (CLCN1) are seen in myotonia congenita, which does not characteristically worsen with cold. Option B (K channel) is not implicated in this condition. Option C (Na Channel) is correct, as paramyotonia congenita is due to mutations in the sodium (SCN4A) channel. 1) Cold-induced worsening of myotonia is a hallmark of paramyotonia congenita. 2) Differentiation between sodium and chloride channel myotonias is critical, as treatment responses differ. 3) Genetic testing for SCN4A mutations is essential for confirming the diagnosis. Recent advancements in genetic analysis have further refined our understanding of muscle channelopathies. Studies continue to validate the use of mexiletine and other sodium channel blockers in managing paramyotonia congenita, with ongoing research into more targeted therapies and safety profiles during pregnancy and lactation.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Parkinsonism symptoms not responding to Sinemet with dystonia and abnormal movements.",
    "option_a": "CBD",
    "option_b": "LBD",
    "option_c": "PSP",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinsonism is defined by motor symptoms including bradykinesia, rigidity, and tremor. In idiopathic Parkinson's disease, these symptoms typically respond to levodopa (Sinemet). However, atypical parkinsonian syndromes\u2014such as Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP), and Lewy Body Dementia (LBD)\u2014often exhibit poor or transient responses to levodopa and display additional features like dystonia or abnormal, unsynchronized movements. CBD is a tauopathy characterized by abnormal accumulations of 4-repeat tau protein. This leads to asymmetric neurodegeneration predominantly affecting the cerebral cortex and basal ganglia. The cortical involvement explains the presence of dystonia, apraxia, and unusual involuntary movements, while the poor dopaminergic response indicates that the underlying pathology is not primarily due to dopamine deficiency. Patients with CBD usually have an asymmetrical onset of parkinsonian features with prominent dystonia, cortical sensory loss, and sometimes the 'alien limb phenomenon.' The lack of improvement with Sinemet is a clue that the parkinsonism is secondary to an atypical degenerative process rather than classical Parkinson\u2019s disease. Diagnosis is clinical, aided by neuroimaging. MRI may show asymmetric atrophy, particularly in the frontoparietal regions. It is important to differentiate CBD from PSP (which typically presents with early falls and vertical gaze palsy) and LBD (which has prominent cognitive fluctuations and visual hallucinations). Other neurodegenerative conditions should be considered and ruled out based on clinical presentation and imaging. No curative treatment exists. Management is supportive and revolves around symptomatic control using physical, occupational, and speech therapy. Levodopa trials may be attempted, but benefits are usually limited. For pregnant or lactating patients, any medication use requires a careful risk\u2010benefit analysis; there is limited data on dopaminergic therapies in these populations, so symptom management and multidisciplinary consultation are key. Option A (CBD) is correct as it best fits the description of parkinsonism with dystonia and abnormal movements that does not respond to Sinemet. Option B (LBD) would be expected to present with early dementia and visual hallucinations, while Option C (PSP) is generally characterized by vertical gaze palsy and early postural instability rather than pronounced dystonia. 1. CBD often presents with asymmetric motor symptoms and cortical signs such as apraxia and alien limb phenomenon. 2. A poor response to levodopa is a distinguishing feature from idiopathic Parkinson\u2019s disease. 3. Neuroimaging can help differentiate CBD from other atypical parkinsonian syndromes. Recent research on tauopathies, including CBD, is focusing on potential therapies targeting tau protein aggregation. However, current management remains supportive, with ongoing studies aimed at earlier diagnosis and better symptomatic treatments.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "A patient has TIC and ADHD how to treat (Clonidine was not one of the options)",
    "option_a": "Methylphenidate",
    "option_b": "atomoxetine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "ADHD and tic disorders frequently coexist. Traditionally, there was concern that stimulant medications like methylphenidate might exacerbate tics, although more recent evidence has shown that stimulants can be used safely in many cases while effectively treating ADHD symptoms. ADHD involves dysregulation in dopaminergic and noradrenergic pathways, while tic disorders involve abnormal neural circuits in the cortico-striato-thalamo-cortical loop. Stimulants increase dopamine levels, improving attention and concentration, and studies suggest that they do not consistently worsen tic severity. Patients with comorbid ADHD and tics present with inattentiveness, hyperactivity, and the presence of motor or vocal tics. Despite historical concerns, evidence from controlled studies indicates that methylphenidate is effective for ADHD in these patients without significant tic worsening. Diagnosis is based on clinical history and observation. Differentials include isolated ADHD, Tourette syndrome, and anxiety disorders that might cause tic-like movements. Detailed symptom chronology and response to interventions aid in differentiation. First-line treatment for ADHD typically involves stimulant medications like methylphenidate, even in the presence of tics. Atomoxetine is a non-stimulant alternative that may be used if tics worsen or if there is contraindication to stimulants. For pregnant or lactating women, medication selection requires careful assessment. Often non-pharmacological treatments (behavioral therapy) are considered, and if medication is needed, the safety profile of the chosen agent must be evaluated in consultation with obstetrics and pediatric specialists. Option A (Methylphenidate) is correct because multiple studies support its safe use in children with ADHD and coexisting tic disorders. Option B (Atomoxetine) is a valid alternative but is generally considered second-line to stimulants. The absence of clonidine in the options makes methylphenidate the preferred choice given current evidence. Options C and D are not provided. 1. Stimulants, particularly methylphenidate, remain first-line therapy for ADHD even in patients with tics. 2. Close monitoring is essential when initiating treatment to observe any changes in tic severity. 3. Atomoxetine is reserved for patients who may not tolerate stimulants or who exhibit tic exacerbation. Recent meta-analyses and controlled trials have demonstrated that methylphenidate does not significantly worsen tics and is effective in managing ADHD symptoms, supporting its use as a first-line agent in patients with co-occurring tic disorders.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "30- a child with dopa-responsive dystonia, started with foot dystonia and progressed to Generalized with diurnal variation, what is the diagnosis?",
    "option_a": "DYT1",
    "option_b": ", is correct if it represents dopa",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Dopa-responsive dystonia (DRD), often referred to as Segawa\u2019s disease, is characterized by childhood-onset dystonia with diurnal variation. It typically starts in the lower extremities (foot dystonia) and progresses, showing marked improvement with low-dose levodopa. DRD results from a deficiency in dopamine secondary to reduced activity of the enzyme GTP cyclohydrolase I. The most common cause is a heterozygous mutation in the GCH1 gene, which leads to decreased synthesis of tetrahydrobiopterin (BH4), an essential cofactor in dopamine production. Clinically, DRD presents with dystonia that begins in the foot, progresses to generalized involvement, and shows diurnal fluctuation\u2014symptoms worsen as the day progresses. The dramatic and sustained response to low doses of levodopa helps differentiate it from other forms of dystonia. The diagnosis is primarily clinical, confirmed by a levodopa challenge. Differential diagnoses include DYT1 dystonia (associated with TOR1A mutations) which typically does not show diurnal variation or dramatic levodopa responsiveness. Genetic testing for GCH1 mutations can provide confirmatory evidence. The primary treatment for DRD is low-dose levodopa, which typically results in near-complete symptomatic relief. For pregnant or lactating patients, levodopa is generally considered relatively safe, but treatment decisions should be individualized with a multidisciplinary approach and continuous monitoring. Option A (DYT1) refers to a form of dystonia caused by a mutation in the TOR1A gene and is not typically levodopa-responsive. The marked answer, Option B, is correct if it represents dopa-responsive dystonia (Segawa disease). 1. Diurnal variation is a hallmark of DRD. 2. A trial of low-dose levodopa is both diagnostic and therapeutic. 3. DRD is genetically distinct from DYT1 dystonia, which does not respond to levodopa. Recent studies have reinforced the role of GCH1 mutations in DRD and have refined clinical diagnostic criteria. Ongoing research is exploring novel therapeutic avenues to target the underlying biochemical pathway, although levodopa remains the cornerstone of treatment.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Same scenario of Q30 child with dopa-responsive dystonia what is the gene responsible?",
    "option_a": "TOR1",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Dopa-responsive dystonia (DRD) is a genetically mediated movement disorder most commonly due to a defect in the enzyme responsible for catalyzing the first step in dopamine synthesis. The GCH1 gene encodes the enzyme GTP cyclohydrolase I, essential for the production of tetrahydrobiopterin (BH4), a cofactor required in the synthesis of dopamine. Mutations in GCH1 lead to BH4 deficiency, which in turn causes dopamine deficiency and the characteristic dystonic symptoms of DRD. Clinically, DRD presents in childhood with lower extremity dystonia that progresses and exhibits diurnal variation. The marked, sustained improvement with low-dose levodopa therapy is strongly indicative of the underlying dopamine deficiency resulting from a GCH1 mutation. Diagnosis involves a combination of clinical evaluation (noting diurnal variation and levodopa responsiveness), biochemical testing (if available), and confirmatory genetic testing for GCH1 mutations. Important differentials include DYT1 dystonia, which is linked to TOR1A mutations and does not typically manifest with levodopa responsiveness. The treatment of choice is low-dose levodopa, resulting in dramatic improvement of symptoms. In the context of pregnancy or lactation, levodopa is generally used when the benefits outweigh potential risks, with careful monitoring and interdisciplinary management to ensure maternal and fetal safety. Option A (TOR1) is incorrect, as mutations in TOR1A cause DYT1 dystonia, which differs from DRD in terms of clinical presentation and levodopa responsiveness. The marked answer, Option B, is correct, assuming it denotes the GCH1 gene, which is responsible for DRD. 1. A mutation in the GCH1 gene is the classic cause of DRD. 2. Diurnal fluctuation in symptoms is a key clinical indicator of DRD. 3. DYT1 dystonia, associated with the TOR1A gene, is not responsive to levodopa. Current research consistently confirms that GCH1 mutations underlie the majority of DRD cases. Advances in genetic testing have improved diagnostic accuracy, and ongoing studies are investigating targeted treatments for dopamine synthesis pathway defects, although levodopa remains the standard of care.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient on risperidone how to different tardive dyskinesia from Huntington\u2019s disease",
    "option_a": "family history",
    "option_b": "Lack of eye movement",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Tardive dyskinesia (TD) is a drug\u2010induced movement disorder that usually arises after prolonged exposure to dopamine receptor antagonists (eg, risperidone). In contrast, Huntington\u2019s disease (HD) is an inherited neurodegenerative disorder characterized by choreiform movements, cognitive decline, and behavioral abnormalities. Distinguishing between the two is essential because TD is iatrogenic while HD has a clear genetic basis. TD is thought to result from dopamine receptor upregulation and hypersensitivity due to chronic blockade by antipsychotics. Huntington\u2019s disease is caused by an autosomal dominant expansion of CAG repeats in the huntingtin gene leading to neurodegeneration, particularly of the striatum. These distinct mechanisms underlie the differences in family history and other clinical features between the conditions. Patients with TD often show involuntary orofacial movements and choreoathetoid motions as a side effect of antipsychotic medications. In contrast, HD typically presents with chorea, along with progressive cognitive and psychiatric changes, and usually a positive family history. Eye movement abnormalities (eg, slowed saccades) can be seen in HD but are not described as a 'lack of eye movement.' Key elements include a thorough medication history and family history. In a patient on risperidone with involuntary movements, the absence of a family history of HD supports the diagnosis of TD. Differential diagnoses include idiopathic Parkinson\u2019s disease (with tremor or dyskinesia), drug-induced parkinsonism, and other hereditary choreas. Genetic testing for HD is considered when there is a suggestive family history. Management of TD involves reducing or discontinuing the offending agent if possible and using medications like VMAT2 inhibitors (eg, valbenazine or deutetrabenazine) as first-line treatment. In contrast, HD management is supportive, focusing on symptom control with medications like tetrabenazine, antipsychotics, and supportive therapies. In pregnancy and lactation, medication choices must account for fetal risk; for instance, the use of VMAT2 inhibitors requires careful risk\u2013benefit evaluation. Option A (Family history) is the correct distinguishing factor; a positive family history points toward Huntington\u2019s disease. Option B (Lack of eye movement) is misleading because while some eye movement abnormalities (such as slowed saccades) may be seen in HD, a complete \u2018lack\u2019 of eye movement is not typical of either condition and does not help in differentiation. 1. Always review the medication history when new movement disorders appear, as many are drug-induced. 2. A positive family history is a critical clue to Huntington\u2019s disease. 3. Eye movement abnormalities in HD usually present as slowed saccades, not as an absolute absence. Recent neurology guidelines emphasize the importance of a detailed history and focused physical examination to differentiate TD from neurodegenerative disorders like HD. Genetic testing remains the gold standard when HD is suspected, and updated data support the safety and efficacy of VMAT2 inhibitors in TD management with attention to teratogenic risks in pregnant or lactating patients.",
    "exam_year": "2023",
    "exam_type": "Part II"
  }
]